BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36144246)

  • 21. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.
    Mazziotti G; Formenti AM; Frara S; Olivetti R; Banfi G; Memo M; Maroldi R; Giubbini R; Giustina A
    J Clin Endocrinol Metab; 2018 Mar; 103(3):956-964. PubMed ID: 29121201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of Thyroid-stimulating Hormone Suppression Therapy on Bone Mineral Density in Patients with Differentiated Thyroid Cancer: A Meta-analysis.
    Yoon BH; Lee Y; Oh HJ; Kim SH; Lee YK
    J Bone Metab; 2019 Feb; 26(1):51-60. PubMed ID: 30899725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global skeletal uptake of technetium-99m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer.
    Frusciante V; Carnevale V; Scillitani A; Zingrillo M; Dicembrino F; Giannatempo GM; Ghiggi MR; Minisola S
    Eur J Nucl Med; 1998 Feb; 25(2):139-43. PubMed ID: 9473261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma.
    Kim CW; Hong S; Oh SH; Lee JJ; Han JY; Hong S; Kim SH; Nam M; Kim YS
    J Bone Metab; 2015 Aug; 22(3):135-41. PubMed ID: 26389089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis.
    Franklyn JA; Betteridge J; Holder R; Sheppard MC
    Thyroid; 1995 Oct; 5(5):359-63. PubMed ID: 8563472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy.
    Vera L; Gay S; Campomenosi C; Paolino S; Pera G; Monti E; Mortara L; Seriolo B; Giusti M
    Endokrynol Pol; 2016; 67(4):350-8. PubMed ID: 27387240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurements of Bone Health after Thyroid-Stimulating Suppression Therapy in Postmenopausal Women with Differentiated Thyroid Carcinoma: Bone Mineral Density versus the Trabecular Bone Score.
    Chung CW; Choi HS; Kong SH; Park YJ; Park DJ; Ahn HY; Cho SW
    J Clin Med; 2021 May; 10(9):. PubMed ID: 34063726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Body composition changes in patients with differentiated thyroid cancer after iodine-131 treatment and short-term levothyroxine replacement and suppression therapy.
    Wang R; Qin S; Qiao T; Jiang W; Tong J; Lu G; Gao D; Zhang M; Lv Z; Li D; Chai L
    Hormones (Athens); 2024 Jan; ():. PubMed ID: 38277093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TSH-suppressive therapy can reduce bone mineral density in patients with differentiated thyroid carcinoma: a meta-analysis.
    Wang MY; Han ZQ; Gong XW; Li Q; Ma J
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):922-929. PubMed ID: 32016999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C; Golia F; Vignali E; Pinchera A
    J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone mineral density in male patients with L-thyroxine suppressive therapy and Graves disease.
    Jódar E; Martínez-Díaz-Guerra G; Azriel S; Hawkins F
    Calcif Tissue Int; 2001 Aug; 69(2):84-7. PubMed ID: 11683428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
    Sajjinanont T; Rajchadara S; Sriassawaamorn N; Panichkul S
    J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S71-6. PubMed ID: 16858944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma.
    Kim MK; Yun KJ; Kim MH; Lim DJ; Kwon HS; Song KH; Kang MI; Baek KH
    Bone; 2015 Feb; 71():101-5. PubMed ID: 25445448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women.
    Larijani B; Gharibdoost F; Pajouhi M; Sadjadi A; Aghakhani S; Eshraghian R; Akrami SM; Maalouf G
    J Clin Pharm Ther; 2004 Feb; 29(1):1-5. PubMed ID: 14748891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy.
    Garton M; Reid I; Loveridge N; Robins S; Murchison L; Beckett G; Reid D
    Clin Endocrinol (Oxf); 1994 Dec; 41(6):747-55. PubMed ID: 7889610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bone mineral density in patients on long-term therapy with levothyroxine].
    Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
    Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac Effects of Thyrotropin Oversuppression with Levothyroxine in Young Women with Differentiated Thyroid Cancer.
    Hong KS; Son JW; Ryu OH; Choi MG; Hong JY; Lee SJ
    Int J Endocrinol; 2016; 2016():9846790. PubMed ID: 27418929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.
    Ku EJ; Yoo WS; Lee EK; Ahn HY; Woo SH; Hong JH; Chung HK; Park JW
    J Clin Endocrinol Metab; 2021 Nov; 106(12):3655-3667. PubMed ID: 34302730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
    Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
    Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.